The PARTNER 3 study compared transcatheter aortic valve replacement (TAVR) with surgical replacement (SAVR) in 1,000 patients with low surgical risk and severe symptomatic aortic stenosis[2][3]. After seven years, there were no significant differences between the groups in the primary outcome of death, stroke, or rehospitalization (34.6% for TAVR versus 37.2% for SAVR)[2]. Mortality was similar in both groups (19.5% for TAVR versus 16.8% for SAVR), as was the incidence of stroke (8.5% versus 8.1%)[2]. Aortic valve function was comparable - mean gradients were 13.1 mm Hg after TAVR and 12.1 mm Hg after surgery[3]. Bioprosthesis failure occurred in 6.9% of cases after TAVR and in 7.3% of cases after surgery[3]. TAVR had fewer cases of atrial fibrillation, but more cases of need for pacemaker implantation and paravalvular regurgitation[2]. The conclusion of the study confirms that in low-risk patients the long-term results of both methods are similar[3].